中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

376 records (took 0.028 seconds)

    RESIDENCE STRUCTURES AND RELATED METHODS
    23.
    发明申请
    RESIDENCE STRUCTURES AND RELATED METHODS 有权

    公开(公告)号：US20210093564A1

    公开(公告)日：2021-04-01

    申请号：US16899447

    申请日：2020-06-11

    Applicant: Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

    Inventor： Andrew Bellinger ,  Shiyi Zhang ,  Carlo Giovanni Traverso ,  Robert S. Langer ,  Stacy Mo ,  Tyler Grant ,  Mousa Jafari ,  Dean Liang Glettig ,  Angela DiCiccio ,  Lowell L. Wood ,  Philip A. Eckhoff

    IPC: A61K9/00 ,  C08G18/73 ,  C08G63/08 ,  C08G18/42 ,  A61K47/58 ,  A61K47/69 ,  A61K9/48 ,  A61K31/357 ,  A61K31/65 ,  A61K31/7048 ,  C08G83/00 ,  A61K47/32 ,  C08L33/02 ,  C08L33/08 ,  C08L33/14 ,  A61K47/10 ,  A61K47/34 ,  A61K47/40 ,  A61K47/42 ,  A61M31/00

    Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

    COMPONENTS WITH HIGH API LOADING
    29.
    发明申请
    COMPONENTS WITH HIGH API LOADING 审中-公开

    公开(公告)号：US20200324095A1

    公开(公告)日：2020-10-15

    申请号：US16614172

    申请日：2018-05-17

    Applicant: Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

    Inventor： Carlo Giovanni Traverso ,  Alex G. Abramson ,  Ester Caffarel Salvador ,  Niclas Roxhed ,  Minsoo Khang ,  Taylor Bensel ,  Robert S. Langer

    IPC: A61M37/00 ,  A61K9/00 ,  A61K38/28 ,  A61K9/48

    Abstract: Components with relatively high loading of active pharmaceutical ingredients are generally provided. In some embodiments, the component (e.g., a tissue interfacing component) comprises a solid therapeutic agent and a supporting material such that the solid therapeutic agent is present in the component in an amount of greater than or equal to 10 wt % versus the total weight of the tissue interfacing component. Such tissue-interfacing components may be useful for delivery of API doses e.g., to a subject. Advantageously, in some embodiments, the reduction of volume required to deliver the required API dose as compared to a liquid formulation permits the creation of solid needle delivery systems for a wide variety of drugs in a variety of places/tissues (e.g., tongue, GI mucosal tissue, skin) and/or reduces and/or eliminates the application of an external force in order to inject a drug solution through the small opening in the needle. In some cases, a physiologically relevant dose may be present in a single tissue interfacing component.

    TISSUE ANCHORING ARTICLES
    30.
    发明申请
    TISSUE ANCHORING ARTICLES 审中-公开

    公开(公告)号：US20200306515A1

    公开(公告)日：2020-10-01

    申请号：US16614299

    申请日：2018-05-17

    Applicant: Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

    Inventor： Carlo Giovanni Traverso ,  Alex G. Abramson ,  Ester Caffarel Salvador ,  Niclas Roxhed ,  Minsoo Khang ,  Taylor Bensel ,  David Dellal ,  Robert S. Langer

    IPC: A61M31/00 ,  A61M5/20 ,  A61M5/32 ,  A61M37/00 ,  A61K9/00 ,  A61K9/48

    Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject).

Patent Agency Ranking